SALARIUS PHARMACEUTICALS INC (SLRX)

Company Profile

Salarius Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.

Company Info

SALARIUS PHARMACEUTICALS INC

2450 Holcombe Blvd Ste J-608

Houston TEXAS 77021

P: 13467720346

CEO: David J. Arthur

Employees: 2

Website: https://salariuspharma.com/